MedicureTSXV:MPH 52 Gross Margin % is 44.31% as of Mar. 2026, which is 31% below its 10-year median of 64.22. GuruFocus rates TSXV:MPH with a GF Score™ of 52/100 and a GF Value™ of C$1.56 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 943 Drug Manufacturers companies, Medicure ranks worse than 65.96% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Medicure's Gross Profit for the
three
months ended in Mar. 2026 was C$3.52 Mil. Medicure's Revenue for the
three
months ended in Mar. 2026 was C$7.95 Mil. Therefore, Medicure's Gross Margin % for the quarter that ended in Mar. 2026 was 44.31%.
Warning Sign:
Medicure Inc gross margin has been in long-term decline. The average rate of decline per year is -1.2%.
The historical rank and industry rank for Medicure's Gross Margin % or its related term are showing as below:
TSXV:MPH'
s Gross Margin % Range Over the Past 10 Years
Min: 39.68 Med: 64.22 Max: 87.3
Current: 39.68
During the past 13 years, the highestGross Margin % of Medicure was 87.30%. The lowest was 39.68%. And the median was 64.22%.
TSXV:MPH's Gross Margin % is ranked worse than 65.96% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs TSXV:MPH: 39.68
Medicure had a gross margin of 44.31% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Medicure was -1.20% per year.
Medicure (TSXV:MPH) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medicure had a gross margin of 44.31% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medicure Gross Margin % Related Terms
Medicure Gross Margin % Historical Data
* Premium members only.
The historical data trend for Medicure's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicure Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicure's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medicure's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medicure (TSXV:MPH) has a Gross Margin % of 44.31% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Medicure and its competitors. This is 31% below median its historical median of 64.22. Over the past decade, Medicure's Gross Margin % has ranged from 39.68 to 87.30. According to the industry distribution chart, Medicure ranks #622 out of 943 companies in the Drug Manufacturers industry, placing it in the top 66%.
Is Medicure's Gross Margin % too high?
Medicure's current Gross Margin % of 44.31% is 31% below median its 10-year median of 64.22. Over the past 10 years, this metric has ranged from a low of 39.68 to a high of 87.30. The Drug Manufacturers industry median Gross Margin % is 48.54. Medicure's value of 44.31% is 8.7% below this industry median. Based on the distribution chart, Medicure ranks #622 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medicure has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicure's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #622 out of 943 companies for Gross Margin %. This places Medicure in the lower half of its industry. The industry median Gross Margin % is 48.54. Medicure's value of 44.31% is 8.7% below this benchmark. Historically, Medicure's own Gross Margin % has ranged from 39.68 to 87.30 over the past decade. While the company's 10-year median is 64.22 vs. the industry median of 48.54, Medicure has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicure's current Gross Margin % of 44.31% is 8.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medicure and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicure's current Gross Margin % is 44.31%, which is 31% below median its own 10-year median of 64.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Based on GuruFocus' analysis, Medicure (TSXV:MPH) is currently considered Possible Value Trap. The stock's GF Value™ is C$1.56, compared to a current price of C$1.06 — trading 32.1% below its estimated fair value. The current Gross Margin % is 44.31%, which is 31% below median its 10-year median of 64.22 and 8.7% below the Drug Manufacturers industry median of 48.54. Medicure's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medicure (TSXV:MPH), the current Gross Margin % is 44.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicure (TSXV:MPH) Overvalued in 2026?
Based on GuruFocus' analysis, Medicure stock appears to be undervalued.
The current stock price of C$1.06 is trading 32.1% below its estimated GF Value™ of C$1.56.
GuruFocus considers Medicure to be Possible Value Trap.
Key valuation signals for TSXV:MPH:
Gross Margin %: 44.31% (31% below median its 10-year median of 64.22)
GF Value™: C$1.56 vs. price of C$1.06 (32.1% below fair value)
Industry Position: 8.7% below the Drug Manufacturers median (#622 of 943)
No single metric tells the full story. See the TSXV:MPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
52GF Score
Get the complete analysis for TSXV:MPH
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:MPH has been successfully added to your 
